Skip to main content

Teladoc Health Inc

For the period ended Dec 31, 2024. Filed Feb 27, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 27, 2025

TDOC$8.94-0.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 8. Consolidated Statements of Cash Flows

Consolidated Statements of Cash Flows

(in thousands)

Year EndedDecember 31,
202420232022
Cash flows from operating activities:
Net loss$(1,001,245)$(220,368)$(13,659,531)
Adjustments to reconcile net loss to net cash flows from operating activities:
Goodwill impairment790,000—13,402,812
Amortization of intangible assets363,365325,933244,620
Depreciation of property and equipment10,18311,13811,407
Amortization of right-of-use assets9,29511,65011,757
Provision for allowances for doubtful accounts3,7954,6862,815
Stock-based compensation145,951201,550217,852
Deferred income taxes(1,145)(1,903)(7,840)
Other, net9,7965,69213,788
Changes in operating assets and liabilities:
Accounts receivable(375)(10,252)(49,058)
Prepaid expenses and other current assets5,18812,461(41,081)
Inventory(9,749)24,09514,800
Other assets(1,257)(23,052)(27,767)
Accounts payable(10,365)(4,185)1,876
Accrued expenses and other current liabilities30,1789,06961,217
Accrued compensation(20,499)19,180(12,290)
Deferred revenue(18,246)(4,900)15,240
Operating lease liabilities(10,892)(10,224)(11,525)
Other liabilities(298)(549)200
Net cash provided by operating activities293,680350,021189,292
Cash flows from investing activities:
Capital expenditures(10,790)(11,464)(16,480)
Capitalized software development costs(113,262)(144,884)(156,284)
Proceeds from marketable securities——2,507
Other, net—12,514
Net cash used in investing activities(124,052)(156,347)(167,743)
Cash flows from financing activities:
Proceeds from the exercise of stock options3,5661,4815,884
Proceeds from employee stock purchase plan4,7489,6516,501
Other, net(2)(278)(5,888)
Net cash provided by financing activities8,31210,8546,497
Net increase in cash and cash equivalents177,940204,52828,046
Effect of foreign currency exchange rate changes(3,288)965(3,344)
Cash and cash equivalents at beginning of the period1,123,675918,182893,480
Cash and cash equivalents at end of the period$1,298,327$1,123,675$918,182
Cash paid for income taxes, net$8,946$7,238$2,512
Interest paid$17,322$17,422$17,361
Supplemental disclosure of non-cash investing activities
Accruals related to Property and equipment, net and Intangible assets, net$4,351$11,006$8,216
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.